96 related articles for article (PubMed ID: 23728853)
1. Population pharmacokinetics of carvedilol in patients with congestive heart failure.
Nikolic VN; Jankovic SM; Velickovic-Radovanović R; Apostolović S; Stanojevic D; Zivanovic S; Stefanovic N; Pesic S; Jevtovic-Stoimenov T; Djuric J; Markovic V; Milovanovic JR
J Pharm Sci; 2013 Aug; 102(8):2851-8. PubMed ID: 23728853
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
Saito M; Kawana J; Ohno T; Hanada K; Kaneko M; Mihara K; Shiomi M; Nagayama M; Sumiyoshi T; Ogata H
Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
Biol Pharm Bull; 2007 Mar; 30(3):537-42. PubMed ID: 17329852
[TBL] [Abstract][Full Text] [Related]
4. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
[TBL] [Abstract][Full Text] [Related]
5. Serum carvedilol concentration and its relation to change in plasma brain natriuretic peptide level in the treatment of heart failure: a preliminary study.
Konishi H; Nishio S; Tsutamoto T; Minouchi T; Yamaji A
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):578-86. PubMed ID: 14692707
[TBL] [Abstract][Full Text] [Related]
6. Should pharmacotherapy of digoxin be reviewed in male patients with heart failure in the case of association with carvedilol?
Souza FC; Neri JS; Marques EB; Barros RB; Scaramello CB
Int J Cardiol; 2015 Jul; 191():4-6. PubMed ID: 25957928
[No Abstract] [Full Text] [Related]
7. Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits.
Spaeder J; Najjar SS; Gerstenblith G; Hefter G; Kern L; Palmer JG; Gottlieb SH; Kasper EK
Am Heart J; 2006 Apr; 151(4):844.e1-10. PubMed ID: 16569544
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.
Giessmann T; Modess C; Hecker U; Zschiesche M; Dazert P; Kunert-Keil C; Warzok R; Engel G; Weitschies W; Cascorbi I; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2004 Mar; 75(3):213-22. PubMed ID: 15001973
[TBL] [Abstract][Full Text] [Related]
9. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
Shihmanter R; Nulman I; Goland S; Caspi A; Bar-Haim A; Harary I; Berkovitch M; Arcavi L
J Clin Pharm Ther; 2014 Aug; 39(4):432-8. PubMed ID: 24673480
[TBL] [Abstract][Full Text] [Related]
10. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure.
Albers S; Meibohm B; Mir TS; Läer S
Br J Clin Pharmacol; 2008 Apr; 65(4):511-22. PubMed ID: 17995971
[TBL] [Abstract][Full Text] [Related]
12. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure.
Tenero DM; Henderson LS; Campanile AM; Baidoo CA; Boyle D
Am J Cardiol; 2006 Oct; 98(7A):27L-31L. PubMed ID: 17023229
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure.
Horiuchi I; Nozawa T; Fujii N; Inoue H; Honda M; Shimizu T; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2008 May; 31(5):976-80. PubMed ID: 18451529
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics and heart failure: a convergence with carvedilol.
Meadowcroft AM; Williamson KM; Patterson JH; Pieper JA
Pharmacotherapy; 1997; 17(4):637-9. PubMed ID: 9250542
[No Abstract] [Full Text] [Related]
16. Enantioselective and highly sensitive determination of carvedilol in human plasma and whole blood after administration of the racemate using normal-phase high-performance liquid chromatography.
Saito M; Kawana J; Ohno T; Kaneko M; Mihara K; Hanada K; Sugita R; Okada N; Oosato S; Nagayama M; Sumiyoshi T; Ogata H
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Oct; 843(1):73-7. PubMed ID: 16784906
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers.
Honda M; Nozawa T; Igarashi N; Inoue H; Arakawa R; Ogura Y; Okabe H; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2005 Aug; 28(8):1476-9. PubMed ID: 16079496
[TBL] [Abstract][Full Text] [Related]
18. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
19. Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol.
Bertera FM; Di Verniero CA; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharmacol Toxicol Methods; 2009; 59(1):13-20. PubMed ID: 18973819
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]